Cancer communications (London, England) · 2021
The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tang Ling-Long, Chen Yu-Pei, Chen Chuan-Ben, Chen Ming-Yuan, Chen Nian-Yong, Chen Xiao-Zhong, Du Xiao-Jing, Fang Wen-Feng, Feng Mei, Gao Jin, Han Fei, He Xia, Hu Chao-Su, Hu De-Sheng, Hu Guang-Yuan, Jiang Hao, Jiang Wei, Jin Feng, Lang Jin-Yi, Li Jin-Gao, Lin Shao-Jun, Liu Xu, Liu Qiu-Fang, Ma Lin, Mai Hai-Qiang, Qin Ji-Yong, Shen Liang-Fang, Sun Ying, Wang Pei-Guo, Wang Ren-Sheng, Wang Ruo-Zheng, Wang Xiao-Shen, Wang Ying, Wu Hui, Xia Yun-Fei, Xiao Shao-Wen, Yang Kun-Yu, Yi Jun-Lin, Zhu Xiao-Dong, Ma Jun
Аннотация
Nasopharyngeal carcinoma (NPC) is a malignant epithelial tumor originating in the nasopharynx and has a high incidence in Southeast Asia and North Africa. To develop these comprehensive guidelines for the diagnosis and management of NPC, the Chinese Society of Clinical Oncology (CSCO) arranged a multi-disciplinary team comprising of experts from all sub-specialties of NPC to write, discuss, and revise the guidelines. Based on the findings of evidence-based medicine in China and abroad, domestic experts have iteratively developed these guidelines to provide proper management of NPC. Overall, the guidelines describe the screening, clinical and pathological diagnosis, staging and risk assessment, therapies, and follow-up of NPC, which aim to improve the management of NPC.